Xeltis Showcases aXess Clinical Progress at Nephrology Conference

According to a recent LinkedIn post from Xeltis, senior clinical and business development leadership will attend the American Society of Diagnostic and Interventional Nephrology 22nd Annual Scientific Meeting in Florida in February 2026. The post notes participation by the Vice President of US Clinical Affairs and the Vice President of Clinical Business Development, indicating a focus on clinical engagement with the nephrology community.

The company’s LinkedIn post highlights that Dr. Adrian Sequira of Louisiana State Health Sciences Centre is scheduled to present updates on the clinical progress of aXess, described as Xeltis’ restorative vascular access conduit. This visibility at a specialized nephrology conference may help validate the aXess program among key opinion leaders, potentially supporting future adoption and reimbursement discussions.

The post suggests that Xeltis is advancing aXess toward commercialization and is open to meetings with stakeholders during the event. For investors, active conference participation and emerging clinical data could signal progress along the regulatory and commercial pathway in the vascular access and dialysis market, although concrete timelines, regulatory status, and financial implications are not detailed in the post.